Kanabo Research has signed an agreement with Constance Therapeutics from the US
Tel-Aviv, ISRAEL, April 25, 2018 - Israeli startup Kanabo Research, which develops clinical solutions for extraction and vaporization of medical cannabis, announces it is entering an agreement with Constance Therapeutics, a US-based medical cannabis extraction company.
According to the agreement, both companies will operate in the EU to establish a cannabis cultivation farm as well as manufacturing capabilities of cannabis active compounds – THC and CBD – to be used in an array of medical treatments and chronic ailments such as insomnia, PTSD and chronic pain. Simultaneously, Constance Therapeutics will market Kanabo Research’s solutions in the US market where Constance Therapeutics has been operating since 2008.
“We are happy to join hands with a medical cannabis market leader like Constance Therapeutics which will allow us to strengthen our presence in the American market” said Avihu Tamir, co-founder and CEO of Kanabo Research. “At the same time, we are operating to locate global opportunities in light of the fact that many countries are asking to join the medical cannabis revolution. The move will allow us to accelerate our manufacturing pace – especially important now because of the delays in medical cannabis export approvals in Israel – and will provide us with an excellent base for additional operations in other markets, primarily European markets".
Kanabo Research has seen significant momentum in the last few months. Recently, the company received initial approvals from Israel’s Ministry of Health to use cannabis with its proprietary VapePod vaporizer. Similarly, the company has commenced pre-clinical trials of Kanabo’s proprietary formulations that focus on sleep disorders and in the future for patients suffering from PTSD.
About Kanabo Research
Israeli Startup Kanabo Research conducts research and development of medical cannabis extraction and vaporization solutions. Kanabo’s vaporization device – VapePod – allows patients to inhale natural cannabis and increase effectiveness without any smoke. Similarly, the device, which is patent protected, lets patients monitor the dosage precisely and over time. Kanabo’s extraction pods, which are based on extensive medical trials and in cooperation with leading doctors in Israel and around the world, provide treatments that target central nervous system disorders affecting sleep, anxiety and chronic pain.
The company was founded in 2016 by CEO, Avihu Tamir, and COO, David Sack. Among the partners and investors are David Tsur, Co-founder and former Chief Executive Officer of Kamada Ltd. (NASDAQ: KMDA). Dr. Doron Friedman, CTO with over 25 years’ experience as a biomedical entrepreneur and executive. Dr. Friedman is the inventor of Bausch and Lomb’s Lotemax eye drops, and holds over 80 patents. And Dr. Nachshon Knoler, world-renowned neurosurgeon, currently Director of the Department of Neurosurgery at Sheba Medical Center in Tel-Hashomer, Israel.
Kanabo Research operates in the Science Park at Weitzman Institute.